President Trump is expected to unveil a major policy shift aimed at lowering drug costs under Medicaid, directing all 50 states to adopt "most favored nation" pricing—a strategy that ties U.S. drug prices to lower rates paid by other developed nations. The announcement, set to take place in the Oval Office alongside several governors, reflects growing political pressure to address skyrocketing medication expenses amid voter concerns over affordability. The move could reshape how states negotiate drug prices, potentially saving billions in healthcare spending while sparking debate over its broader impact on pharmaceutical markets. Supporters argue it will make critical medications more accessible, but critics may question whether the approach goes far enough to curb rising costs for patients nationwide.
President Trump on Friday is set to announce that all 50 states will see "most favored nation" (MFN) pricing for some drugs covered by Medicaid, according to an administration official. Trump will be joined by "several governors" in the Oval Office to make the announcement, the official said. With affordability a top concern among voters,...
